Ind-Swift to upgrade Jammu plant to EUGMP and PICS, targets Rs 100 cr extra revenue
INDSWFTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.0 pts less than Nifty Microcap 250 and 6.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Ind-Swift Laboratories plans to upgrade its Jammu manufacturing facility to EU-GMP and PICS standards to access European and other regulated export markets. Total planned investment is around Rs. 45 crores. The plant is expected to be compliant by early 2028, targeting additional revenue of Rs. 100 crores from FY 2029-30. The facility, built in 2008 across 14,700 sq meters, currently serves domestic and soft regulated markets and makes oral solid dosage and ointments. It will support CDMO and own branding. Q1 FY27 operating income rose 21% YoY to Rs. 186 cr.
Opens EU regulated markets, adding Rs 100 cr revenue from FY30, but Rs 45 cr capex and a long wait until 2029-30.